Beruflich Dokumente
Kultur Dokumente
METHOD
Box 1 Current International Statistical Classication of Consensus development process
Diseases and Related Health Problems (ICD-10) Four major topics were chosen by core members of the orga-
classication of gastritis (K29 code) http://apps.who.int/ nising committee (KS, NU and PM). Drafts of clinical ques-
classications/icd10/browse/2015/en#/K29 tions (CQs) about each topic were prepared by the ad hoc
committee of the Japanese Society of Gastroenterology
( JSGE) and were further revised by core members (KS, PM
K29 Gastritis and duodenitis
and EME-O). Altogether, 23 CQs were selected for the rst
Excl: eosinophilic gastritis or gastroenteritis (K52.8)
round of voting.
ZollingerEllison syndrome (E16.4)
Faculty members were selected from members of the JSGE,
K29.0 Acute haemorrhagic gastritis
European Helicobacter Study Group, Asian Pacic Association
Incl: Acute (erosive) gastritis with haemorrhage
of Gastroenterology, Healthy Stomach Initiative and the
Excl: erosion (acute) of stomach (K25.)
working group members of gastroenterology for ICD-11. These
K29.1 Other acute gastritis
members were assigned to one of the four subgroups by core
K29.2 Alcoholic gastritis
members (KS, NU and PM) based on their expertise and two
K29.3 Chronic supercial gastritis
members from each subgroup were invited to serve as modera-
K29.4 Chronic atrophic gastritis
tors. The faculty members of each group were assigned one or
Incl: Gastric atrophy
two CQs for which they were asked to prepare statements and
K29.5 Chronic gastritis, unspecied
supporting evidence. These statements were edited by modera-
Incl: Chronic gastritis
tors and core members and uploaded to the electronic voting
Antral
system developed by JSGE.
Fundal
The Delphi method was used for consensus development, and
K29.6 Other gastritis
voting by each faculty member was done anonymously through
Incl: Giant hypertrophic gastritis
the electronic system. Each faculty member was asked to indi-
Granulomatous gastritis
cate one of the following levels of agreement: strongly agree,
Mntrier disease
agree with minor reservation, agree with major reservation, dis-
K29.7 Gastritis, unspecied
agree with minor reservation, disagree with major reservation
K29.8 Duodenitis
and strongly disagree. If the members vote was other than
K29.9 Gastroduodenitis, unspecied
strongly agree or agree with minor reservation, they were asked
Excl, exclusion criteria; Incl, inclusion criteria. to give the reasons for reservation or disagreement.
Consensus level was predened as 80% of the sum of the
votes of strongly agree plus agree with minor reservation.
dyspeptic symptoms in the context of the clinical assessment of After the rst round of voting, moderators in each subgroup
FD still remains.5 1012 Accordingly, guidelines and meta-analyses initiated further discussion about the statements which had
that included dyspepsia associated with H. pylori under the failed to reach consensus. After this discussion, the revised
umbrella of functional dyspepsia5 1012 would require reconsid- statements were uploaded to the electronic voting system for
eration in accordance with advances made in the area of a second round of voting. This process resulted in several
H. pylori gastritis. CQs being modied for improved understanding and to
Third, there has been signicant technical progress in diagnos- better t the statements. At the second round of voting,
tic tools for GI diseases. Advanced endoscopy with image- faculty members were asked to provide recommendation as to
enhanced modalities and magnication allows diagnosis of gastri- the grade of evidence and the levels of supporting evidence
tis with a high degree of accuracy, even before histological con- for the statements. Recommendation grade and evidence level
rmation.1315 Furthermore, non-invasive diagnostic tests such as were based on the GRADE system21 22 (see online supplemen-
the [13C]-urea breath test, faecal antigen test and serological para- tary table S1 and S2). Electronic reminders were automatically
meters serve as surrogate markers of H. pylori gastritis and indi- sent to all faculty members twice (3 days and 1 day before the
cators of gastritis severity.5 Classication systems for grading closing dates). Voting rates of 100% were achieved in the two
gastritis such as the Operative Link for Gastritis Assessment voting sessions.
(OLGA) and Operative Link for Gastric Intestinal Metaplasia The second round of voting was followed by a face-to-face
Assessment (OLGIM) have also been proposed,1618 in addition meeting in Kyoto on 31 January to 1 February 2014. On the
to the internationally accepted Sydney System,19 20 and their rst day, preliminary plenary voting was conducted since
utility needs to be evaluated and agreed upon. faculty members had hitherto been blinded to the voting
In 2013, the Japanese government insurance policy approved results in other sections. This process identied several state-
eradication therapy for H. pylori-positive gastritis after endo- ments which failed to achieve consensus of 80%. Each
scopic examination, to exclude more serious diseases such as group then met to resolve disagreements and better reect
ulcer and cancer, in line with the Japanese guidelines for opinions from all group members. On the second day, the
H. pylori management.11 However, no global consensus has revised statements were presented at plenary discussions with
been published on when to recommend eradication therapy for all group members. Voting for each statement was done using
H. pylori gastritis and how to follow up after eradication. a key pad system with the levels of agreements being shown
Since the global awareness of gastritis is still confounded by a on the screen in real time. Statements that failed to reach con-
number of controversial issues as described above, a meeting sensus were discussed, revised if considered necessary and
was set up in Kyoto to achieve global consensus on H. pylori voted on again. Finalised statements were summarised by
gastritis; to attempt conceptual changes in gastritis classication moderators assigned to each group.
in general; to agree diagnosis and management strategies with The ve colleagues who could not attend the face-to-face
special reference to FD and cancer prevention. meeting or missed the nal voting were invited later to give
1354 Sugano K, et al. Gut 2015;64:13531367. doi:10.1136/gutjnl-2015-309252
Guidelines
gastritis varies according to the extent and severity of inamma- CQ6. Is H. pylori gastritis an infectious disease irrespective of
tion and atrophy. symptom and complications?
Grade of recommendation: strong Statement 6
Evidence level: high H. pylori gastritis should be dened as an infectious disease,
Consensus level: 100% even when patients have no symptoms and irrespective of com-
plications such as peptic ulcers and gastric cancer.
Grade of recommendation: strong
Comment
Evidence level: high
The updated Sydney System has been globally implemented into
Consensus level: 100%
clinical practice and requires proper assessment of all the rele-
vant characteristics of H. pylori gastritis including atrophy
Comment
and intestinal metaplasia at different gastric subsites.19 20
H. pylori gastritis is an infectious disease and leads to chronic active
Categorising gastritis is clinically relevant because the pheno-
gastritis of varying severity in virtually all infected subjects.50
type of H. pylori gastritis determines the risk of progression to
There is a signicant variability in the interindividual expres-
gastroduodenal complications.
sions of gastric mucosal structural damage and accordingly the
Severity and extent of atrophic gastritis and intestinal
associated physiological perturbations also vary.30 35 H. pylori
metaplasia are well established as indicators of the increased risk
gastritis may remain clinically unapparent or evolve into severe
for developing gastric cancer.31 39 40 Similarly, severe
complications. The rate of progression is unpredictable. The
H. pylori-induced corpus gastritis is associated with an increased
most severe clinical expression is gastric cancer, which is often
risk for gastric cancer.31 41 New staging systems for the charac-
incurable by the time of diagnosis.
terisation of gastritis have been introduced to assess the gastric
Cure of H. pylori infection leads to healing of the inamed
cancer risk. They are used in clinical practice and are either
gastric mucosa, which may return to normal. H. pylori eradica-
based on the severity of atrophy in various gastric subsites
tion may improve or resolve dyspeptic symptoms and usually
(OLGA)16 17 or on intestinal metaplasia (OLGIM).18 Both
cures PUD. H. pylori gastritis is a disease which can be cured
systems, discussed further in section 3, are reported to have a
and thus prevent severe complications. If H. pylori gastritis has
positive impact on patient management.
progressed to more severe forms of gastritis, including atrophic
gastritis with or without intestinal metaplasia, or severe corpus
CQ5. How should we classify gastric erosions in the context of
predominant gastritis, the risk of gastric cancer is increased and
chronic gastritis?
eradication of the infection at this stage needs to be integrated
Statement 5
with a follow-up strategy.5 11 28 31 36 40
Gastric erosions should be reported separately from gastritis.
The natural history and clinical signicance of gastroduodenal
Section 2 Dyspepsia associated with H. pylori infection
erosions depend on aetiology and need further clarication.
CQ7. Does H. pylori gastritis cause dyspepsia?
Grade of recommendation: strong
Statement 7
Evidence level: low
H. pylori gastritis is the cause of dyspepsia in a subset of patients.
Consensus level: 100%
Grade of recommendation: strong
Evidence level: high
Comment Consensus level: 100%
Gastric erosions are dened as supercial mucosal breaks with a
diameter of <3 mm or <5 mm.42 This small size makes it less Comment
likely to confound erosions with peptic ulcers which, by den- A large number of observations support the conclusion that
ition, penetrate the muscularis mucosae.3 H. pylori infection may be a cause of symptoms in a proportion
Gastric erosions can be detected in the context of H. pylori of patients presenting with dyspepsia.26 27 First, acute iatrogenic
infection but are more frequently caused by intake of mucosal or self-administered infection with H. pylori can induce acute
damaging drugsin particular, aspirin and non-steroidal anti- dyspeptic symptoms.24 25 However, while persistent colonisation
inammatory drugs (NSAIDs).43 44 virtually always leads to chronic gastritis,48 in the majority of
Furthermore, several different morphological forms were individuals severe dyspeptic symptoms are transient.24 25 51
noted after eradication of H. pylori as (a) at, (b) raised, Second, most but not all, epidemiological studies show associa-
(c) haemorrhagic and (d) appearing as bleeding spots with local- tions between H. pylori infection and (uninvestigated) dyspeptic
isation in the antrum in the absence of drugs,45 possibly owing symptoms.5255 The most convincing evidence can be derived
to hyperacidity after eradication therapy.46 47 from H. pylori eradication studies in infected patients with unin-
From a clinical perspective, the most relevant aspect of ero- vestigated or FD.12 5661 In these studies, eradication is associated
sions is that patients taking NSAIDs and having numerous ero- with a small but statistically signicant benet for symptom
sions in the stomach are at increased risk of developing ulcers control over no eradication; the estimated number needed to
subsequently.48 treat is 1412 and in a more recent study the number was 8.61 At
Few studies on the clinical signicance or natural history of present there are no criteria to predict whether a patient with
gastric or duodenal erosions have been reported. Thus, it is dyspeptic symptoms will respond to eradication therapy or not.
important to conduct a prospective research in which erosions in Therefore, the only way in clinical practice is to eradicate the
the stomach and duodenum are separately reported in conjunc- H. pylori infection and see whether symptoms resolve or
tion with the category of gastritis, which is needed to better whether additional treatments will be required. The symptomatic
understand the natural history of gastric erosions and their gain takes at least 6 months to become signicant over no eradi-
potential to progress to ulceration and bleeding. Validated scores cation and this has been attributed to the time it takes for gastritis
for reporting erosions for research purposes should be used.49 to recover.12 5961
CQ8. Should we categorise H. pylori-associated dyspepsia as a patients with FD derive symptomatic benet from eradication,
specic entity? with a delay of at least 6 months from cure of the infection.12 5961
Statement 8A Based on these considerations, sustained symptom control
In H. pylori-infected patients with dyspepsia, symptoms can be after successful eradication identies H. pylori as the organic
attributed to H. pylori gastritis if successful eradication therapy cause of the symptoms in these patients and provides the ration-
is followed by sustained symptom remission. ale to consider H. pylori-associated dyspepsia as a separate clin-
Grade of recommendation: strong ical entity. H. pylori-infected patients with chronic dyspeptic
Evidence level: high symptoms and negative endoscopy are now treated and labelled
Consensus level: 97.4% depending on their treatment response as outlined in gure 1.
Statement 8B
H. pylori-associated dyspepsia (as in statement 8A) is a distinct CQ9. Is eradication of H. pylori infection rst-line treatment
entity. for improving dyspeptic symptoms?
Grade of recommendation: strong Statement 9
Evidence level: moderate Eradication of H. pylori is rst-line treatment for
Consensus level: 92.1% H. pylori-infected dyspeptic patients.
Grade of recommendation: strong
Evidence level: high
Comment Consensus level: 94.7%
Based on the Rome III consensus,9 62 FD is dened as the pres-
ence of chronic dyspeptic symptoms ( postprandial fullness,
Comment
early satiation, epigastric pain or burning) without evidence of
As is apparent from statement 8, there is a group of patients
structural disease (including at upper endoscopy) that is likely to
with FD for whom H. pylori is considered the cause of their
explain the symptoms (gure 1). This group was contrasted
symptoms, and this can be established if eradication is associated
with those in whom chronic dyspeptic symptoms have an identi-
with sustained symptom benet.9 5961 This scenario is the only
ed organic or metabolic cause, where elimination of that cause
one where patients with chronic dyspeptic symptoms and a
or improvement of the disease leads to resolution or improve-
negative endoscopy can be cured, albeit with some delay after
ment of symptoms.9
successful eradication therapy.12 5961 Moreover, very few effect-
The Rome III consensus mentions a subset of patients with
ive alternative therapeutic approaches have been proved to have
H. pylori gastritis as representative of organic dyspepsia if they
substantial and sustained benet in FD.63 Finally, eradication
respond to eradication. Patients with H. pylori gastritis in whom
therapy is a short treatment, with acceptable costbenet for
symptoms persist despite eradication therapy eliminating the infec-
controlling dyspeptic symptoms, and with other potential bene-
tion were identied as having FD.9 As mentioned above, eradica-
ts for prevention of peptic ulcer and gastric cancer.5 Based on
tion therapy studies showed that a subset of H. pylori-infected
these considerations, eradication therapy can be proposed as
rst-line treatment for H. pylori-infected dyspeptic patients,
which is in line with a recent management algorithm by the
Rome foundation.64
Comment
Eradication therapy studies have conrmed that a subset of
H. pylori-infected patients with FD is relieved of dyspeptic
symptoms by eradication therapy.12 5661 To date, only a limited
number of studies have directly compared eradication therapy
with other treatments that are used for FD, such as PPIs or pro-
kinetic therapy.57 60 61 Hence, although the symptomatic gain
takes at least 6 months,57 60 61 eradication is the preferred treat-
Figure 1 Diagnostic algorithm of Helicobacter pylori-associated ment. Future trials should compare eradication with treatment
dyspepsia. Patients with dyspeptic symptoms after negative routine
modalities other than placebo in H pylori-infected patients with
laboratory and upper gastrointestinal endoscopy except for positive
H. pylori tests, should undergo eradication therapy. If sustained chronic dyspeptic symptoms and a negative endoscopy.
symptomatic relief is obtained, their dyspeptic symptoms are considered
as H. pylori-associated dyspepsia. On the other hand, if dyspeptic CQ11. Should patients who remain dyspeptic after successful
symptoms do not resolve or recur after eradication therapy, they are H. pylori eradication be considered to have FD?
judged to have functional dyspepsia. EGD, oesophagastroduodenoscopy. Statement 11
Sugano K, et al. Gut 2015;64:13531367. doi:10.1136/gutjnl-2015-309252 1359
Guidelines
Patients who remain symptomatic after successful H. pylori diagnosis of premalignant gastric lesions. This includes chro-
eradication should be considered to have FD. moendoscopy,65 high-resolution magnication endoscopy66 67
Grade of recommendation: weak and image-enhanced endoscopy combined with magnica-
Evidence level: moderate tion15 6872 (gure 2). These methods are now routinely available
Consensus level: 97.4% in Japan and will be increasingly used worldwide. Adequate
evaluation of the stomach mucosa with each of these methods
Comment
requires appropriate training66 and offers the advantage of tar-
As indicated in statements 8A and 8B and in agreement with the
geted biopsies.
Rome III criteria,9 62 H. pylori infected dyspeptic patients with
negative endoscopy who experience sustained symptom control
CQ13. Is the updated Sydney System appropriate for histo-
are labelled as having H. pylori-associated dyspepsia.
logical diagnosis of gastritis?
Conversely, when symptoms do not benet in the long term
Statement 13
from successful eradication, this indicates that H. pylori gastritis
Accurate histological assessment of gastritis requires biopsy sam-
did not cause the symptoms in these patients. Consequently,
pling of both antrum and corpus.
they can keep the label functional dyspepsia (gure 1).
Grade of recommendation: strong
Section 3 Diagnosis of gastritis Evidence level: high
CQ12. Is it possible to make a diagnosis of atrophy and/or Consensus level: 92.1%
intestinal metaplasia by endoscopy?
Statement 12 Comment
Atrophic mucosa and intestinal metaplasia can be accurately Premalignant lesions of the stomach may be unevenly distribu-
detected by image-enhanced endoscopy, after appropriate training. ted. Therefore, accurate histological assessment of gastritis
Grade of recommendation: strong requires biopsy sampling of both antrum and corpus. This may
Evidence level: high facilitate the classication and grading of preneoplastic gastric
Consensus level: 84.2% lesions.73 Various studies have shown that more extensive
biopsy sampling increases the diagnostic yield for identifying
Comment patients with premalignant lesions and provides a better over-
Conventional endoscopy is, in most hands, an inadequate tool view of the severity and distribution of these lesions.7476
for diagnosing atrophy and intestinal metaplasia and therefore it This also has practical limitations, which led to the updated
remains mandatory that a biopsy is carried out, allowing histo- Sydney System. This provides guidance on the methods of
morphological assessment of the gastric mucosa according to the sampling and the histopathological grading of individual
Sydney classication.19 20 However, image-enhanced endoscopy abnormalitiesin particular, inammation, gland loss and
has improved the accuracy and reproducibility of endoscopic metaplasia.20 The Sydney System recommends routine
Figure 2 Image enhanced endoscopy. (A) Narrow band imaging (NBI) of the gastric mucosa. Round homogeneous sized pits with regularly
arranged collecting venules are shown (left). This pattern (regular arrangement of collecting venules) named RAC pattern in the corpus mucosa
highly indicates a Helicobacter pylori negative state.13 In the H. pylori-infected mucosa with inammation, pit patterns are elongated, varied in sizes
and shapes with spaces between them. Collecting venules are obscured owing to inammation (centre).14 When intestinal metaplasia develops, the
pit pattern is further elongated with light blue lines (light blue crest sign) decorating the pits margins (right).66 The images were provided by
Dr Kazuyoshi Yagi. (B) Blue laser imaging (BLI) of the gastric mucosa. BLI is a new modality of image enhancement.70 The BLI-bright mode can
easily obtain lower magnication images, similar to the NBI images in (A) (left). With BLI-magnication mode, further mucosal details including
periglandular capillary networks (red coloured circles surrounding the pits) are seen (centre). BLI endoscopy is useful for identifying the area of
intestinal metaplasia where greenish coloured elongated pit patterns predominate (right). The images were provided by Dr Hiroyuki Osawa, Jichi
Medical University.
1360 Sugano K, et al. Gut 2015;64:13531367. doi:10.1136/gutjnl-2015-309252
Guidelines
sampling of ve gastric biopsy specimens: antrum greater and CQ15. Are serological tests ( pepsinogen I, II, I/II, H. pylori
lesser curvature, incisura and corpus greater and lesser curva- antibody) useful for risk stratication?
ture. Specimens need to be put into separate vials and grouped Statement 15
for each site or lesion. The system is widely used; the most Serological tests ( pepsinogen I and II and H. pylori antibody)
common modication being to leave out the separate incisura are useful for identifying individuals at increased risk for gastric
sample.36 It is of key importance that separate specimens are cancer.
obtained from endoscopically visible lesions. The accuracy of Grade of recommendation: strong
image-enhanced endoscopy in trained hands further increases Evidence level: high
the yield of targeted biopsies.66 77 78 Consensus level: 91.9%
CQ14. Are grading systems such as OLGA and OLGIM useful Comment
for risk stratication? Serological tests for the diagnosis of chronic gastritis and gastric
Statement 14A atrophy have been in use for more than 25 years. These include
Gastric cancer risk correlates with the severity and extent of H. pylori serology (crude antigen with or without additional
atrophic gastritis. determination of anti-CagA antibodies) for the diagnosis of gas-
Grade of recommendation: strong tritis, and serum pepsinogen I and II and gastrin for the diagno-
Evidence level: high sis of gland loss resulting in hypoacidity.85 These tests are
Consensus level: 94.7% usually applied in panels of multiple tests and have been shown
Statement 14B to be a useful non-invasive diagnostic tool in an individual
Histological staging systems such as OLGA and OLGIM are patient, and as a population screening and surveillance tool.86 87
useful for risk stratication. A Japanese cohort of 9293 screenees underwent serological
Grade of recommendation: strong assessment by means of H. pylori serology and pepsinogen I
Evidence level: low and II measurement.86 The annual progression to gastric cancer
Consensus level: 97.3% was very low in subjects with normal pepsinogens, irrespective
of H. pylori status. The annual progression to gastric cancer was
Comment substantially higher (3.56 per 1000 per year) in individuals
Most gastric cancers are triggered by longstanding gastritis, pri- with low serum pepsinogen levels, compatible with presence of
marily due to H. pylori infection. This can occur via a multistep atrophic gastritis.86 In the latter group, the incidence of gastric
pathway of precancerous lesionsin particular, atrophic gastri- cancer was higher among those with negative H. pylori serology
tis, intestinal metaplasia and dysplasia/intraepithelial neoplasia. than among those with positive H. pylori serology, which is
Various studies conrm an increased gastric cancer risk in indicative of progressive and widespread atrophy and metaplasia
patients with premalignant gastric lesions. For instance, a impairing further H. pylori colonisation. Similar ndings were
nationwide study from the Netherlands including approximately obtained in other studies.88 89
98 000 patients with premalignant gastric lesions reported, on
average, a 23% gastric cancer risk over 10 years.79 This risk CQ16. When is it appropriate to search and screen for
varied with the baseline stage of premalignant lesions, being H. pylori gastritis?
0.8%, 1.8%, 3.9% and 32.7% for patients with atrophic gastri- Statement 16
tis, intestinal metaplasia, mild-to-moderate dysplasia and severe Depending on the epidemiological context, it is appropriate to
dysplasia, respectively.79 search and screen for H. pylori gastritis at an age before devel-
These data conrmed the association between presence of opment of atrophic gastritis and intestinal metaplasia.
premalignant gastric lesions and development of gastric cancer, Grade of recommendation: strong
yet also showed that the risk for developing gastric cancer in an Evidence level: moderate
individual with premalignant lesions is nevertheless small (26 Consensus level: 97.3%
per 1000 people per year). This necessitates the use of risk
stratication methods.
Gastric biopsy sampling can be used to provide the most Comment
important information for risk classication. This led to the H. pylori infection is mainly acquired in childhood, up to the age
OLGA staging system.16 17 This histological staging system of 12 years, in developed countries mostly by intrafamilial trans-
grades patients with gastritis into stages with corresponding mission.9092 The bacterium and associated gastritis persist life-
gastric cancer risk. Further studies showed that this staging long, unless treated by eradication therapy, or unless end-stage
system provides relevant clinical information.8082 Based on the widespread atrophic gastritis and intestinal metaplasia occur. The
high prevalence of atrophic gastritis in at-risk populations and risk for gastric cancer depends on the grade of gastric atrophy
the limited reproducibility and high interobserver variability in and intestinal metaplasia.31 8284 86 H. pylori eradication can
histological diagnosis of atrophic gastritis, a further proposal reduce the risk for cancer, but this effect is largely conned to
was made for the OLGIM system based on diagnosis and distri- patients without atrophy and metaplasia.9395 In patients with
bution of intestinal metaplasia.18 these lesions, H. pylori eradication reduces gastritis, but may not
The interobserver reproducibility was improved for intestinal stop further progression to cancer. As a result, cancer can occur
metaplasia compared with atrophic gastritis, and the correlation more than 10 years after H. pylori eradication treatment.96
between the severities of gastritis remained at least as strong.18 Against this background, it is appropriate to search and screen
Subsequent studies with both the OLGA and OLGIM systems for H. pylori gastritis at an age when new infections become less
showed a higher gastric cancer risk in patients in stage III or IV likely (>12 years) and before development of atrophic gastritis
of OLGA or OLGIM.8284 As a result, upper gastrointestinal and intestinal metaplasia. This all depends on the geographical
surveillance endoscopy should be offered to patients in these location and epidemiological context, taking into account the
subcategories. prevalence of infection and age-related cancer incidence.97
Sugano K, et al. Gut 2015;64:13531367. doi:10.1136/gutjnl-2015-309252 1361
Guidelines
different regions and this, in part, dictates what regimens are preferably using a non-invasive test such as a urea breath test or a
possible. validated monoclonal-based stool antigen test.5 For patients
Grade of recommendation: strong requiring endoscopic follow-up, such as after endoscopic
Evidence level: high removal of a gastric adenoma, histological assessment can be
Consensus level: 100% used. Conrmation of cure also provides an early warning system
for the increasing antibiotic resistance in a population that will
Comment
manifest as increasing rates of treatment failure.125 128 129
The success of a proven successful H. pylori eradication regimen
depends on the pattern of resistance in the population and on
CQ22. Which patients need long-term follow-up after eradication?
the common host genotypes of drug metabolising enzymes in
Statement 22
the population. The prevalence of H. pylori resistance to com-
H. pylori eradication may not completely eliminate the risk of
monly used antimicrobial agents greatly varies geographically
gastric cancer. Patients who remain at risk, as dened by the
and is linked to consumption of antibiotics in the region,125 so
extent and severity of atrophy, should be offered endoscopic
the preferred eradication regimen often differs between regions.
and histological surveillance.
Ideally, treatment regimens should be chosen based on suscepti-
Grade of recommendation: strong
bility testing. Within any region, only regimens that reliably
Evidence level: high
produce eradication rates of 90% in that population should be
Consensus level: 97.3%
used for empirical treatment.5 126129
Comment
CQ20. Does eradication of H. pylori prevent gastric cancer?
Long-term follow-up such as regular endoscopic surveillance
Statement 20
should be based on estimating the risk of developing gastric cancer
Eradication of H. pylori reduces the risk of gastric cancer. The
after H. pylori eradication (ie, risk stratication).95 133 Cancer risk
degree of risk reduction depends on the presence, severity and
correlates with the extent and severity of atrophic gastritis and risk
extent of atrophic damage at the time of eradication.
stratication should be conrmed using a validated histological
Grade of recommendation: strong
risk scoring systems such as OLGA or OLGIM.1618 In areas with
Evidence level: high
proven expertise in endoscopic scoring, a system such as that of
Consensus level: 100%
Kimura and Takemoto can be used initially, although histological
Comment conrmation is still recommended.134 135 Patients whose H. pylori
H. pylori infection is the most important cause of gastric cancer infection was diagnosed non-invasively (eg, urea breath test or
as it is estimated that 89% of non-cardia gastric cancer, repre- stool antigen) should be considered for histological assessment.
senting 78% of all cases of gastric cancer, can be attributed to These patients should include those within the age range in which
chronic H. pylori infection.130 Prevention of H. pylori infections atrophic changes are common in that population and those with a
removes the primary cause of gastric cancer and will thus history of gastric ulcer as well as those with a pretreatment serum
reduce the incidence of gastric cancer in that population. The pepsinogen I of 70 ng/mL and a pepsinogen I:II ratio 3.136138
effectiveness of H. pylori eradication for prevention of gastric All those at especially high risk, including those at risk for intrae-
cancer depends on the severity and extent of atrophic damage pithelial neoplasia (dysplasia) or early gastric cancer, are candidates
at the time of eradication and ranges from essentially complete for regular endoscopic surveillance.
prevention for those with non-atrophic gastritis to stabilisation
or reduction of risk in those with established atrophic DISCUSSION
changes.94 95 As noted in Section 3, risk can be stratied using a The global consensus meeting on H. pylori gastritis has set a
variety of approaches, such as one of the validated histological new landmark for gastritis, which has continued to be an ill-
stratication systems (eg, OLGA or OLGIM),1618 and H. pylori conceived clinical entity placed between a histological picture
eradication can stabilise risk and halt the progression of and upper abdominal symptoms.
risk.28 94 Prevention of acquisition of H. pylori infections and In spite of the fact that gastritis had been long recognised as
eradication of the infection before the development of atrophic an important clinical entity, generations of gastroenterologists
changes are forms of primary prevention. Secondary prevention have neglected the importance of treatment of this nosological
involves identication and surveillance of those at risk in order entity. Rudolf Schindler described chronic gastritis as a serious
to remove intraepithelial lesions and early gastric cancer(s) disease and a precursor of gastric cancer and considered their
before they become invasive.5 71 72 77 131 There may be also a relationship as being of outstanding importance in the ght
role for cancer immunotherapy to treat premalignant lesions against gastric cancer.139
and halt their progression to more advanced lesions.132 The discovery of H. pylori has revolutionised the pre-existing
concepts of gastritis by assigning a specic aetiology to this
CQ21. Should the outcome of eradication therapy always be entity underlying PUD and gastric cancer. The majority of these
assessed (ie, test for cure)? serious conditions are manifestations developed on the back-
Statement 21 ground of chronic gastritis caused by a unique infectious agent,
The outcome of eradication therapy should always be assessed, H. pylori. For PUD, guidelines unanimously recommend eradi-
preferably non-invasively. cation as the primary treatment for those with positive H. pylori
Grade of recommendation: strong tests. However, there has been no consensus on how and when
Evidence level: high to manage individuals with H. pylori gastritis itself, which is
Consensus level: 100% crucial to the efciency of gastric cancer prevention because
most patients with chronic gastritis may remain asymptomatic
Comment until the appearance of severe complications. Furthermore, both
Failure of eradication is common and allows the mucosal damage gastritis and duodenitis were recognised as important causes of
to progress, and so eradication should always be conrmed, upper gastrointestinal bleeding,140 encouraging our attention to
Sugano K, et al. Gut 2015;64:13531367. doi:10.1136/gutjnl-2015-309252 1363
Guidelines
these conditions now that anti-thrombotic therapies are increas- Author afliations
1
ingly being used. Department of Medicine, Jichi Medical University, Tochigi, Japan
2
Translational Research Center for Gastrointestinal Disorders, University of Leuven,
To further compromise the concept of gastritis as a signicant Leuven, Belgium
clinical entity, the term gastritis has historically, but wrongly, 3
Department of Gastroenterology and Hepatology, Erasmus MC University Medical
been used as a substitute for a clinical diagnosis of FD. Center, Rotterdam, Netherland
4
Historical studies, however, failed to demonstrate a signicant Department of Medicine, Michael E DeBakery VA Medical Center, Baylor College of
association between histological ndings of gastritis and the dys- Medicine, Houston, USA
5
Division of Applied Medicine, Institute of Medical Sciences, Aberdeen University,
peptic symptom complex.141 142 Hence, a potential pathogen- Aberdeen, UK
etic role for H. pylori in causing dyspeptic symptoms was 6
National Defense Medical College, Tokorozawa, Japan
7
initially considered doubtful and its eradication in FD controver- Department of Gastroenterology, Kawasaki Medical School, Kurashiki, Japan
8
sial.143 144 Meta-analysis of a large number of controlled trials Department of Cancer Preventive Medicine, Hokkaido University, Sapporo, Japan
9
Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan
with longer follow-up conrmed that eradication of H. pylori in 10
Department of Gastroenterology, University of Magdeburg, Magdeburg, Germany
patients with FD conveys a small but statistically signicant
benet.12 Consequently, dyspepsia attributable to H. pylori gas-
Correction notice This article has been corrected since it published Online First.
tritis involves an underlying organic cause and should be Hidekazu Suzuki has been added to the collaborators list.
excluded from the FD category. Additionally, dyspeptic patients
should not automatically be labelled as having gastritis without Acknowledgements We thank the Japanese Society of Gastroenterology (JSGE)
any histological conrmation. for providing nancial support, enabling this global consensus meeting. Technical
Diagnostic assessment of gastritis has been advanced by the support by Omura Publishing Co Ltd and Mr Osamu Iimura of the JSGE is greatly
appreciated. We also thank Japan Convention Service Co Ltd for their excellent
recent introduction of high-resolution endoscopy with image- management of the conference.
enhanced modalities, and magnication is now used routinely in
Collaborators List of faculty members and afliations (alphabetical order of family
major hospitals in Japan. This endoscopic technology allows the names): Takeshi Azuma, Department of Gastroenterology, Kobe University; Franco
identication of mucosal changes (for targeted biopsies) more pre- Bazzoli, Department of Gastroenterology, University of Bologna; Francis Ka-Leung
cisely, leading to more accurate evaluation of cancer risks such as Chan, Department of Medicine and Therapeutics, The Chinese University of Hong
preneoplastic changes. Wider use of this new endoscopic system Kong; Minhu Chen, Department of Gastroenterology, The rst afliated hospital,
SunYat-sen University; Naoki Chiba, McMaster University; Tsutomu Chiba,
outside Japan may be limited at present. Department of Gastroenterology, Kyoto University; Luiz Gonzaga Vas Coelho,
The Kyoto consensus meeting focused attention on gastritis in Department of Internal Medicine, Faculty of Medicine, Federal University of Minas
all its clinical expression and dealt with four main topics: classi- Gerais; Francesco Di Mario, Department of Clinical Experimental Medicine, University
cation of gastritis in relation to ongoing ICD revision, FD and of Parma; Kwong Ming Fock, Department of Gastroenterology, Changi General
H. pylori infection, diagnosis of gastritis and the management Hospital; Yasuhiro Fukuda, Sasayama Medical Center, Hyogo College of Medicine;
Takahisa Furuta, Center for Clinical Research, Hamamatsu University School of
of gastritis. The methodology of the meeting adopted all Medicine; Robert Maximilian Genta, Department of Pathology, Miraca Life Sciences
modern means for reaching consensus and included an internet- Research Institute and University of Texas Southwestern; Khean-Lee Goh, Division of
based Delphi method with full access to published data in a Gastroenterology and Hepatology, Department of Medicine, University of Malaya;
completely neutral environment. Masanori Ito, Department of Gastroenterology and Metabolism, Hiroshima
University, Tomonori Kamada, Department of Internal Medicine, Kawasaki Medical
In summary, The Kyoto meeting proposed an aetiology-based School; Peter Harry Katelaris, Department of Gastroenterology, Concord Hospital,
classication for gastritis and concluded that H. pylori gastritis University of Sidney; Mototsugu Kato, Division of Endoscopy, Hokkaido University
is an infectious disease. As such, H. pylori gastritis requires treat- Hospital; Takashi Kawai, Endoscopy Center, Tokyo Medical University Hospital;
ment whether or not it is associated with symptoms because it Nayoung Kim, Department of Internal Medicine, Seoul National University Bundang
represents a condition that may evolve towards serious compli- Hospital; Ryuji Kushima, Department of Pathology, Shiga University of Medical
Science; Varocha Mahachai, Division of Gastroenterology, Chulalongkorn University
cations, including peptic ulcer and gastric neoplasia. Hospital; Takeshi Matsuhisa, Nippon Medical School Tama Nagayama Hospital;
Consensus was reached on the existence of a separate cat- Francis Mgraud, INSERM U853 and Department of Bacteriology; Hiroto Miwa,
egory of patients with dyspeptic symptoms that are due to Department of Gastroenterology, Hyogo College of Medicine; Kazunari Murakami,
H. pylori gastritis. In these patients, eradication therapy is the Department of Gastroenterology, Oita University; Colm Antoine OMorain, Faculty of
Health Sciences, Trinity College; Massimo Rugge, Department of Pathology, Padova
recommended rst-line treatment. Because of the diagnostic University; Kiichi Sato, International University of Health and Welfare; Tadashi
problems related to gastritis, these patients should be labelled Shimoyama, Department of Gastroenterology and Hepatology, Hirosaki University;
as having H. pylori-associated dyspepsia and are identied by Akiko Shiotani, Department of Internal Medicine, Kawasaki Medical College; Toshiro
sustained dyspeptic symptom relief after eradication. Sugiyama, Department of Internal Medicine, Toyama University; Hidekazu Suzuki,
For the diagnosis of gastritis, it was agreed that risk stratica- Department of Gastroenterology, Keio University; Kazuyoshi Yagi, Department of
Medicine, Niigata Prefectural Yoshida Hospital; Ming-Shiang Wu, Department of
tion systems such as OLGA and OLGIM are useful as are the Internal Medicine, National Taiwan University.
serological markers. In view of recent technological advance-
Contributors KS, NU, EME-O and PM planned the meeting and prepared the
ments, image-enhanced endoscopy should be encouraged for clinical questions. KS, JT, EJK, EME-O, DYG and PM wrote the manuscipt. SM, KH
identifying mucosal changes which carry a high risk of develop- and MA helped to summarise the voting results of sections 1, 3 and 4, respectively.
ing into gastric neoplasia. Finally, it was recommended that All other faculty members contributed to formulating one or two statements for each
early eradication therapy, ideally before preneoplastic changes clinical question, participated in the meeting and voted. They also read and
approved the manuscript.
occur, should be undertaken. However, the feasibility of imple-
menting this strategy should be regionally tailored. As eradica- Competing interests KS has received research grants from Eisai, Daiichi Sankyo
and Takeda. He has also received lecture fees from Astellas, Fuji Film and Takeda. JT
tion therapy does not guarantee elimination of the risk of has provided scientic advice to AlfaWassermann, Almirall, AstraZeneca, Danone, GI
gastric cancer, follow-up should be considered for patients who Dynamics, GlaxoSmithKline, Ironwood, Janssen, Menarini, Novartis, Rhythm, Shire,
have preneoplastic conditions. Sucampo, Takeda, Theravance, Tsumura, Will-Pharma, Yuhan and Zeria. He has also
Although there are still many remaining areas to be discussed, served on speaker bureaus for Abbott, Almirall, AstraZeneca, Danone, Janssen,
we believe the outcome of the Kyoto consensus meeting pre- Menarini, MMS, Novartis, Shire, Takeda and Zeria. He has received research grants
from Novartis, Shire and Zeria. DYG is a consultant for RedHill Biopharma and has
sented in this report will improve patient care and will provide received research support. He is also a consultant for Otsuka Pharmaceuticals and
a cornerstone for further renement and research in the area of for BioGaia. KH has received lecture fees from Astellas, AstraZeneca, Daiich Sankyo,
gastritis. Dainippon Sumitomo, Eisai, Otsuka, Takeda and Zeria. He has also received research